In a patient with end‑stage renal disease and refractory secondary hyperparathyroidism undergoing parathyroidectomy, should sevelamer be continued perioperatively and how should it be managed post‑operatively?

Management of Sevelamer in Parathyroidectomy for Refractory Secondary Hyperparathyroidism

Phosphate binders including sevelamer should be discontinued or substantially reduced immediately after parathyroidectomy, with dosing guided by post-operative serum phosphorus levels, as patients typically develop hypophosphatemia and may require phosphate supplementation rather than binding. 1

Perioperative Management

Pre-operative Considerations

• Continue sevelamer up until surgery if the patient has hyperphosphatemia (serum phosphorus >5.5 mg/dL), as phosphate control remains important before parathyroidectomy 1
• Parathyroidectomy is indicated when PTH levels persistently exceed 800 pg/mL with hypercalcemia and/or hyperphosphatemia refractory to medical therapy 1

Immediate Post-operative Period (First 48-72 Hours)

Discontinue or reduce phosphate binders immediately after surgery based on the following rationale 1:

• The sudden removal of hyperactive parathyroid tissue causes rapid bone remineralization ("hungry bone syndrome") 1
• This creates an acute demand for calcium and phosphate as bone avidly takes up these minerals 1
• Patients typically develop hypophosphatemia rather than hyperphosphatemia post-operatively 1

Monitor serum phosphorus levels closely:

• Check ionized calcium every 4-6 hours for the first 48-72 hours, then twice daily until stable 1
• Simultaneously monitor serum phosphorus levels to guide phosphate binder adjustments 1

Post-operative Management Strategy

Calcium and Vitamin D Replacement (Priority)

When oral intake is possible 1:

• Administer calcium carbonate 1-2 g three times daily 1
• Provide calcitriol up to 2 mcg/day 1
• Adjust doses to maintain ionized calcium in the normal range (1.15-1.36 mmol/L or 4.6-5.4 mg/dL) 1

Phosphate Binder Adjustment Algorithm

If serum phosphorus is low or normal post-operatively:

• Discontinue sevelamer completely 1
• Consider phosphate supplementation if levels fall below normal 1
• Doses should be adjusted upward until normal serum phosphorus is achieved 1

If serum phosphorus remains elevated (uncommon):

• Reduce sevelamer dose substantially rather than continuing pre-operative dosing 1
• Titrate based on serial phosphorus measurements 1

Critical Pitfalls to Avoid

The Hungry Bone Syndrome Risk

• Preoperative and postoperative use of active vitamin D derivatives may reduce the incidence of severe hypocalcemia 1
• Continuing full-dose phosphate binders post-operatively can worsen hypophosphatemia and impair bone remineralization 1
• The metabolic priority shifts from preventing hyperphosphatemia to supporting bone remineralization 1

Long-term Considerations

Sevelamer has specific advantages in the dialysis population 1:

• It is a non-calcium, non-aluminum, non-magnesium phosphate binder that avoids calcium loading 1
• This is particularly important in patients with low PTH levels post-parathyroidectomy who may develop adynamic bone disease 1
• Patients with adynamic bone disease cannot incorporate calcium loads and are at risk for extraskeletal calcification 1

If phosphate binding is needed weeks to months post-operatively:

• Sevelamer may be preferred over calcium-based binders in patients who develop low PTH (<100 pg/mL) 1
• This prevents calcium overload in the setting of low bone turnover 1

Medication Interactions

Be aware that sevelamer can reduce absorption of certain medications 2:

• Cases of increased TSH with levothyroxine co-administration have been reported 2
• Reductions in cyclosporine and tacrolimus concentrations have occurred in transplant patients, though without clinical consequences 2
• Separate administration timing if these medications are used 2

Monitoring Strategy Post-Parathyroidectomy

• Measure ionized calcium every 4-6 hours initially, then twice daily until stable 1
• Check serum phosphorus at least daily during the acute post-operative period 1
• Adjust phosphate binder therapy (or phosphate supplementation) based on these levels 1
• Monitor PTH levels to assess for appropriate suppression and guide long-term mineral metabolism management 1